AFP and hepatoblastoma: However, epidemiology suggests that most tumors in patients with IC2-LoM and hepatoblastoma cases occur within the first 2 years of life, therefore, we adopt the US in IC2-LoM and alphafetoprotein assay every 3 months up to 24–30 months of age for all patients [34].